"Ribavirin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
| Descriptor ID |
D012254
|
| MeSH Number(s) |
D13.570.800.790
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ribavirin".
Below are MeSH descriptors whose meaning is more specific than "Ribavirin".
This graph shows the total number of publications written about "Ribavirin" by people in this website by year, and whether "Ribavirin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ribavirin" by people in Profiles.
-
Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. J Viral Hepat. 2019 10; 26(10):1210-1217.
-
Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings. Infect Dis Clin North Am. 2018 06; 32(2):253-268.
-
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015 Dec 01; 163(11):809-17.
-
Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System. J Manag Care Spec Pharm. 2015 Aug; 21(8):641-7.
-
The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. J Manag Care Pharm. 2013 Jul-Aug; 19(6):438-47.
-
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012 Feb 21; 156(4):263-70.
-
A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis. 2010 Feb; 12(1):38-44.
-
Synergistic activity of purine metabolism inhibitors in cultured human tumor cells. Cancer Lett. 1987 Apr; 35(1):97-104.